Physician profile
Maria Silva
NPI 1790818748
$6,754.86
in general payments reported to CMS, 2019-2025
25 companies · $1,942 in 2025
The $1,942 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $54.37 · 2022: $1,432 · 2023: $1,650 · 2024: $1,677 · 2025: $1,942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,268.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,831.54 | 2022-2025 | |
| Lundbeck LLC | $1,119.06 | 2023-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $732.54 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $514.97 | 2022 | |
| Lilly USA, LLC | $513.74 | 2022-2025 | Emgality, Amyvid, Reyvow |
| Amgen INC. | $354.43 | 2022-2024 | Aimovig |
| Sk Life Science, INC. | $297.28 | 2022-2025 | |
| Emd Serono, INC. | $275.18 | 2022-2025 | Mavenclad |
| Eisai INC. | $192.16 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $173.06 | 2023-2024 | Aptiom |
| Axsome Therapeutics, INC. | $108.34 | 2023-2025 | Sunosi, Symbravo |
| Ucb, INC. | $94.09 | 2022-2023 | Nayzilam, Briviact |
| Sunovion Pharmaceuticals INC. | $85.54 | 2022 | |
| Impel Pharmaceuticals INC. | $75.29 | 2023 | Trudhesa |
| Alexion Pharmaceuticals, INC. | $62.96 | 2023-2024 | Ultomiris |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $53.35 | 2023 | Vumerity, Tysabri, Avonex |
| Jazz Pharmaceuticals INC. | $48.95 | 2024 | |
| Vanda Pharmaceuticals INC. | $46.76 | 2025 | Ponvory |
| Upsher-Smith Laboratories LLC | $37.09 | 2022-2023 | |
| Mdd US Operations, LLC | $31.25 | 2024 | Gocovri |
| Neurelis, INC. | $30.99 | 2022-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $19.57 | 2022 | |
| Horizon Therapeutics Plc | $19.33 | 2022 | |
| Life Molecular Imaging LTD | $19.05 | 2024 | Neuraceq |
| Otsuka America Pharmaceutical, INC. | $18.34 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.